Ultragenyx Pharmaceutical Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 60 LEVERONI COURT, NOVATO, CA, 94949
Mailing Address 60 LEVERONI COURT, NOVATO, CA, 94949
Phone 415-483-8800
Fiscal Year End 1231
EIN 272546083
Financial Overview
FY2024
$1.50B
Total Assets
$1.24B
Total Liabilities
$213.58M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 5, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 8-K Current report of material events | December 30, 2025 | View on SEC |
| 4 Insider stock transaction report | December 30, 2025 | View on SEC |
| 8-K Current report of material events | December 29, 2025 | View on SEC |
Material Events
8-K Strategy Change December 29, 2025
High Impact
- Ultragenyx's experimental drug setrusumab (UX143) failed to meet its primary goal in two late-stage (Phase 3) clinical trials (Orbit and Cosmic) for Osteogenesis Imperfecta (OI).
- The drug did not significantly reduce bone fractures, which was its main objective for regulatory approval.
Insider Trading
SELL 2 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.